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ABSTRACT
Background and Objectives: Transcatheter aortic valve replacement (TAVR) has been 
reported as a good alternative for surgical aortic valve replacement in patients with small 
aortic annulus. Head-to-head comparisons of different transcatheter aortic valves in these 
patients are insufficient. We compared the outcomes after TAVR between two different types 
of recent transcatheter aortic valves (self-expanding vs. balloon-expandable) in patients with 
small aortic annulus.
Methods: A total of 70 patients with severe aortic stenosis and small annulus (mean diameter 
≤23 mm or minimal diameter ≤21 mm on computed tomography) underwent TAVR with 
either a self-expanding valve with supra-annular location (n=45) or a balloon-expandable 
valve with intra-annular location (n=25). The echocardiographic hemodynamic parameters 
after TAVR and 1-year follow-up were compared.
Results: Between the self-expanding and balloon-expandable valve-treated patients, the 
clinical outcomes including permanent pacemaker implantation (11.1% vs. 8.0%), acute 
kidney injury stage 2 or 3 (4.4% vs. 4.0%), and major vascular complication (4.4% vs. 0.0%) 
were similar without all-cause mortality, stroke, and life-threatening bleeding during 30-day 
follow-up. Compared with the balloon-expandable valve-treated patients, the self-expanding 
valve-treated patients presented larger effective orifice area (EOA) (1.46±0.28 vs. 1.75±0.42 
cm2, p=0.002) and indexed EOA (0.95±0.21 vs. 1.18±0.28 cm2/m2, p=0.001), whereas mean 
aortic valve gradient (11.7±2.9 vs. 8.9±5.2 mmHg, P=0.005) and incidence of ≥moderate 
prosthesis-patient mismatch (36.0% vs. 8.9%, p=0.009) were lower. These hemodynamic 
differences were maintained at 1-year follow-up.
Conclusions: TAVR with self-expanding valves was associated with superior hemodynamic 
outcomes compared with balloon-expandable valves in patients with small aortic annulus.
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INTRODUCTION
In patients with symptomatic severe aortic stenosis and small aortic annulus, transcatheter 
aortic valve replacement (TAVR) has been reported as a good alternative to surgical aortic 
valve replacement due to superior hemodynamic outcomes, such as larger effective orifice 
area (EOA) and lower incidence of prosthesis-patient mismatch (PPM).1-4) Currently, there are 
two TAVR technologies available for clinical practice: the self-expanding valve with supra-
annular location, and the balloon-expandable valve with intra-annular location. Studies in 
Europe and the United States have compared the performance of these 2 devices in patients 
with small aortic annulus, and the self-expanding valve has shown superior hemodynamic 
performance compared with the balloon-expandable valve.5)6) Although body size in Asian 
populations is small relative to Western populations, there have been limited studies in Asian 
patients with small aortic annulus who underwent TAVR.7)8) Therefore, the aim of this study 
was to compare the clinical and echocardiographic hemodynamic outcomes after TAVR 
between 2 different types of recent transcatheter aortic valves (self-expanding vs. balloon-
expandable valve) in Korean patients with small aortic annulus.
METHODS
In Korea, SAPIEN 3 valves (Edwards Lifescience, Irvine, CA, USA) were first used in April 
2016, whereas Evolut R and PRO valves (Medtronitc, Minneapolis, MN, USA) were first used 
in August 2015 and January 2019, respectively. Between April 2016 and March 2020, 271 
patients who underwent TAVR for symptomatic severe aortic stenosis at our institute were 
initially identified. Among them, a total of 70 consecutive patients with small aortic annulus 
were included in the analysis. Inclusion criteria were small aortic annulus defined as an 
annulus exhibiting a mean diameter of ≤23 mm or minimal diameter of ≤21 mm on computed 
tomography, and TAVR with either a self-expanding 26 mm Evolut R or PRO valve or a balloon-
expandable 23 mm SAPIEN 3 valve.9) Forty-five patients underwent TAVR with an Evolut 
R (n=37) or a PRO (n=8) valve while 25 patients had a SAPIEN 3 valve. This study complied 
with the principles of the Declaration of Helsinki 2013, and the study protocol was approved 
by Institutional Review Board of our institute. Written informed consent was obtained 
from all patients. For every patient, a multidisciplinary heart team including interventional 
cardiologists, imaging cardiologists, cardiothoracic surgeons, and anesthesiologists made 
decisions for eligibility for TAVR, choice of vascular approach, and type of anesthesia. The 
choice of transcatheter aortic valve type was at the discretion of the operating interventional 
cardiologists. Implantation technique for both valves has been described previously.10)11) The 
rate of permanent pacemaker implantation, early safety outcomes (at 30 days) and 1-year 
clinical outcomes according to the Valve Academic Research Consortium (VARC)-2 consensus, 
and echocardiographic hemodynamic outcomes were analyzed.12) The early safety outcomes 
included all-cause mortality, all stroke, life-threatening bleeding, acute kidney injury stage 
2 or 3, coronary artery obstruction requiring intervention, major vascular complication, and 
valve-related dysfunction requiring repeat procedure. The hemodynamic outcomes based 
on transthoracic echocardiography included EOA, indexed EOA (iEOA), mean aortic valve 
gradient, and PPM. EOA was estimated with the continuity equation and indexed to body 
surface area (BSA) as calculated with the DuBois formula.13) PPM was defined as moderate 
for post-procedural 0.65 cm2/m2< iEOA ≤0.85 cm2/m2 and severe for iEOA ≤0.65 cm2/m2 in 
accordance to the VARC-2 consensus.12) In addition, doppler velocity index was calculated and 
paravalvular leak was assessed and classified as none/trace, mild, moderate, or severe.12)
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Statistical analysis
Continuous variables are reported as mean±standard deviation and were compared using 
Student's t-tests. Categorical variables are reported as number (percentage) and were 
compared using χ2 tests or Fisher's exact tests. Event rates at 1 year were estimated using 
Kaplan-Meier survival analysis and compared using log-rank tests. All tests were two-tailed, 
and a p<0.05 was considered statistically significant. Statistical analysis was performed using 
IBM SPSS, version 23.0 (IBM Corporation, Armonk, NY, USA).
Ethics statement
This study was approved by the Institutional Review Board at Severance Hospital of the 
Yonsei University Health System (1-2009-0018, 1-2011-0099).
RESULTS
Of 271 patients who underwent TAVR for symptomatic severe aortic stenosis between April 2016 
and March 2020, a total of 70 (25.8%) consecutive patients presented with small aortic annulus 
and received either a 26 mm Evolut R or PRO valve (n=45) or a 23 mm SAPIEN 3 valve (n=25). 
Baseline clinical characteristics are presented in Table 1. Across the overall study population, 
mean age was 81.7±4.7 years old and the vast majority of patients were female (92.9%). Body 
mass index was 23.6±3.7 kg/m2, BSA was 1.5±0.2 m2, and 51.4% of patients were in New York 
Heart Association (NYHA) functional class III or IV. The Society of Thoracic Surgeons Predicted 
Risk of Mortality (STS-PROM) score was 5.3±3.5%. Baseline clinical characteristics between the 
self-expanding and balloon-expandable valve-treated groups were similar except for presence 
of NYHA functional class III or IV (64.4% vs. 28.0%, respectively, p=0.008) and the STS-PROM 
score (5.9±4.0% vs. 4.2±1.8%, respectively, p=0.019), which showed that the patients who 
underwent TAVR with a self-expanding valve had more severe symptoms of heart failure and 
higher operative risk. Medications at discharge are presented in Supplementary Table 1.
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Table 1. Baseline clinical characteristics
Overall (n=70) Self-expanding valve (n=45) Balloon-expandable valve (n=25) p value
Age (years) 81.7±4.7 81.7±5.4 81.7±3.4 0.993
Female 65 (92.9) 44 (97.8) 21 (84.0) 0.051
Weight (kg) 54.5±9.8 52.8±9.1 57.4±10.5 0.063
Height (cm) 151.9±7.2 151.0±5.0 153.5±9.9 0.250
Body mass index (kg/m2) 23.6±3.7 23.1±3.6 24.3±3.9 0.197
Body surface area (m2) 1.5±0.2 1.5±0.1 1.6±0.2 0.055
Hypertension 59 (84.3) 37 (82.2) 22 (88.0) 0.735
Diabetes mellitus 29 (41.4) 18 (40.0) 11 (44.0) 0.942
Dyslipidemia 52 (74.3) 31 (68.9) 21 (84.0) 0.271
Chronic kidney disease 25 (35.7) 17 (37.8) 8 (32.0) 0.823
Chronic obstructive pulmonary disease 7 (10.0) 4 (8.9) 3 (12.0) 0.694
Current smoker 2 (2.9) 2 (4.4) 0 (0) 0.534
Coronary artery disease 37 (52.9) 22 (48.9) 15 (60.0) 0.521
Prior myocardial infarction 7 (10.0) 4 (8.9) 3 (12.0) 0.694
Prior percutaneous coronary intervention 17 (24.3) 10 (22.2) 7 (28.0) 0.803
Prior coronary bypass graft surgery 4 (5.7) 2 (4.4) 2 (8.0) 0.613
Peripheral artery disease 13 (18.6) 11 (24.4) 2 (8.0) 0.116
Prior stroke 19 (24.3) 14 (31.1) 3 (12.0) 0.135
Atrial fibrillation 12 (17.1) 9 (20.0) 3 (12.0) 0.517
NYHA functional class III or IV 36 (51.4) 29 (64.4) 7 (28.0) 0.008
STS-PROM (%) 5.3±3.5 5.9±4.0 4.2±1.8 0.019
Data are presented as mean±standard deviation or number (%).
NYHA = New York Heart Association; STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality.
Baseline echocardiographic and computed tomographic characteristics are presented in Table 2.  
Across the overall study population, EOA was 0.67±0.17 cm2 and iEOA was 0.45±0.11 cm2/m2 
by transthoracic echocardiography. In addition, mean annular diameter was 22.2±1.0 mm, 
minimum annular diameter was 19.4±1.2 mm, mean aortic annular area was 379.0±32.0 mm2, 
and mean aortic annular perimeter was 70.2±2.9 mm by computed tomography. Baseline 
computed tomographic characteristics between the two groups were similar, whereas the 
patients who underwent TAVR with a self-expanding valve had more advanced features of 
aortic stenosis on echocardiography. To be specific, compared with the balloon-expandable 
valve-treated patients, the self-expanding valve-treated patients showed smaller EOA 
(0.75±0.14 vs. 0.63±0.18 cm2, p=0.007) and iEOA (0.48±0.10 vs. 0.43±0.11 cm2/m2, p=0.042). 
Procedural characteristics and 30-day clinical outcomes are presented in Table 3. Procedural 
characteristics between the two groups were similar except for post-dilation, which was more 
frequently performed in the self-expanding valve-treated patients (64.4% vs. 8.0% in balloon-
expandable valve-treated patients, p<0.001). The early safety outcomes within 30 days after 
TAVR were comparable between the two groups. At 1-year follow-up, no significant differences 
were observed in terms of all-cause mortality, stroke, myocardial infarction or hospitalization 
for valve-related symptoms or worsening heart failure between the two groups (Table 3).
Hemodynamic outcomes by transthoracic echocardiography at discharge and 1-year follow-
up are shown in Table 4. At discharge, the self-expanding valve-treated patients presented 
significantly larger EOA (1.75±0.42 vs. 1.46±0.28 cm2, p=0.002) and iEOA (1.18±0.28 vs. 
0.95±0.21 cm2/m2, p=0.001) compared with the balloon-expandable valve-treated patients 
(Figure 1A and B). Consequently, the incidence of PPM was significantly less frequent in 
the self-expanding valve-treated patients (8.9% vs. 36.0% in balloon-expandable valve-
treated patients, p=0.009) (Figure 2A). The incidence of more than moderate paravalvular 
leak was similar: 4.4% in the self-expanding valve-treated patients and 4.0% in the 
balloon-expandable valve-treated patients (Figure 2B). These differences in hemodynamic 
outcomes between the 2 groups were maintained at 1-year follow-up. One-year follow-up 
echocardiography was available for 53 patients. At 1-year follow-up, the self-expanding 
valve-treated patients presented significantly larger EOA (1.67±0.32 vs. 1.27±0.44 cm2, 
p<0.001) and iEOA (1.12±0.22 vs. 0.81±0.27 cm2/m2, p<0.001) compared with the balloon-
expandable valve-treated patients (Figure 1A and B). The incidence of PPM was less frequent 
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Table 2. Baseline echocardiographic and computed tomographic characteristics
Overall (n=70) Self-expanding valve (n=45) Balloon-expandable valve (n=25) p value
Baseline echocardiographic characteristics
Effective orifice area (cm2) 0.67±0.17 0.63±0.18 0.75±0.14 0.007
Indexed effective orifice area (cm2/m2) 0.45±0.11 0.43±0.11 0.48±0.10 0.042
Maximum aortic valve pressure gradient (mmHg) 89.1±28.8 93.9±32.6 80.5±17.7 0.029
Mean aortic valve pressure gradient (mmHg) 55.7±18.9 59.4±21.3 49.1±11.0 0.010
Aortic regurgitation (moderate to severe) 13 (18.6) 9 (20.0) 4 (16.0) 0.759
Left ventricular ejection fraction (%) 62.6±14.4 59.9±15.7 67.5±10.4 0.018
Baseline MDCT characteristics
Mean annular diameter (mm) 22.2±1.0 22.1±1.0 22.4±0.9 0.207
Minimum annular diameter (mm) 19.4±1.2 19.2±1.2 19.7±1.2 0.095
Maximum annular diameter (mm) 25.0±1.5 25.0±1.4 25.1±1.5 0.761
Mean aortic annular area (mm2) 379.0±32.0 374.8±32.6 386.6±30.0 0.142
Mean aortic annular perimeter (mm) 70.2±2.9 69.9±3.1 70.7±2.6 0.303
Porcelain aorta 3 (4.3) 3 (6.7) 0 (0) 0.548
Data are presented as mean±standard deviation or number (%).
MDCT = multidetector computed tomographic.
in the self-expanding valve-treated patients (11.4% vs. 66.7% in balloon-expandable valve-
treated patients, p<0.001) with no patients with severe PPM, while 33.3% of the balloon-
expandable valve-treated patients presented severe PPM (Figure 2A). The incidence of 
more than moderate paravalvular leak remained similar: 5.7% in the self-expanding valve-
treated patients and 5.6% in the balloon-expandable valve-treated patients (Figure 2B). The 
echocardiographic characteristics at baseline, discharge, and 1-year follow-up between the 
self-expanding 23 mm valve-treated patients and balloon-expandable 20 mm valve-treated 
patient are presented in Supplementary Table 2.
DISCUSSION
The main findings of this study are as follows: 1) Among Korean patients who underwent 
TAVR, a considerable percentage (25.8%) of patients presented with small aortic annulus. 
2) TAVR in these patients was both effective and safe, and no significant difference in 
clinical outcomes was observed between the self-expanding and balloon-expandable 
valve-treated patients. 3) However, TAVR with the self-expanding valve was associated with 
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Table 3. Procedural characteristics and clinical outcomes




Transfemoral approach 70 (100.0) 45 (100.0) 25 (100.0) 1.000
General anesthesia 54 (77.1) 38 (84.4) 16 (64.0) 0.098
Pre-dilation 45 (64.3) 26 (57.8) 19 (76.0) 0.206
Post-dilation 31 (44.3) 29 (64.4) 2 (8.0) <0.001
Combined percutaneous coronary intervention 6 (8.6) 5 (11.1) 1 (4.0) 0.410
Need for second valve implantation 1 (1.4) 1 (2.2) 0 (0) 1.000
30-day Clinical outcomes
Permanent pacemaker implantation 7 (10.0) 5 (11.1) 2 (8.0) 1.000
Ventricular perforation 0 (0) 0 (0) 0 (0) NA
Conversion to open surgery 0 (0) 0 (0) 0 (0) NA
Early safety outcomes
All-cause mortality 0 (0) 0 (0) 0 (0) NA
All stroke 0 (0) 0 (0) 0 (0) NA
Bleeding* 12 (17.1) 9 (20.0) 3 (12.0) 0.517
Major 2 (2.9) 1 (2.2) 1 (4.0)
Minor 10 (14.3) 8 (17.8) 2 (8.0)
Acute kidney injury 5 (7.1) 4 (8.9) 1 (4.0) 0.648
Stage 1 2 (2.9) 2 (4.4) 0 (0)
Stage 2 3 (4.3) 2 (4.4) 1 (4.0)
Stage 3 0 (0) 0 (0) 0 (0)
Coronary artery obstruction requiring intervention 0 (0) 0 (0) 0 (0) NA
Vascular complication 19 (27.1) 14 (31.1) 5 (20.0) 0.471
Major 2 (2.9) 2 (4.4) 0 (0)
Minor 17 (24.3) 12 (26.7) 5 (20.0)
Valve-related dysfunction requiring repeat procedure 0 (0) 0 (0) 0 (0) NA
One-year clinical outcomes†
All-cause mortality 2 (4.5) 0 (0) 2 (11.6) 0.070
All stroke 0 (0) 0 (0) 0 (0) NA
Myocardial infarction 1 (1.9) 1 (3.0) 0 (0) 0.448
Hospitalization for valve-related symptoms or worsening heart failure 2 (3.6) 2 (5.8) 0 (0) 0.267
NYHA functional class III or IV‡ 3 (5.0) 2 (5.1) 1 (4.8) 1.000
Data are presented as number (%).
NA = not applicable; NYHA = New York Heart Association.
*There was no life-threatening bleeding event. †One-year clinical outcome data are presented as number (% of the cumulative rates at 1 year according to 
Kaplan-Meier event rates, p values are from log-rank tests). ‡One-year NYHA functional class was available in 60 (85.7%) patients.
more hemodynamic benefits with larger EOA, lower aortic valve pressure gradient, and 
consequently, lower incidence of PPM.
For current clinical practice, TAVR technology can be primarily classified into two types 
of valves: the self-expanding valve with supra-annular location or the balloon-expandable 
valve with intra-annular location. Although each type of valve has its own advantages and 
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Table 4. Echocardiographic characteristics at discharge and 1-year follow-up
Overall (n=70) Self-expanding valve (n=45) Balloon-expandable valve (n=25) p value
At discharge n=70 n=45 n=25
Effective orifice area (cm2) 1.65±0.40 1.75±0.42 1.46±0.28 0.002
Indexed effective orifice area (cm2/m2) 1.10±0.28 1.18±0.28 0.95±0.21 0.001
Maximum aortic valve pressure gradient (mmHg) 19.7±9.0 17.5±9.7 23.6±5.7 0.001
Mean aortic valve pressure gradient (mmHg) 9.9±4.7 8.9±5.2 11.7±2.9 0.005
Doppler velocity index 0.61±0.15 0.66±0.14 0.51±0.10 <0.001
Prosthesis-patient mismatch 13 (18.6) 4 (8.9) 9 (36.0) 0.009
Moderate 12 (17.1) 4 (8.9) 8 (32.0)
Severe 1 (1.4) 0 (0.0) 1 (4.0)
Paravalvular leak 29 (41.4) 21 (46.7) 8 (32.0) 0.347
Mild 26 (37.1) 19 (42.2) 7 (28.0)
Moderate 3 (4.3) 2 (4.4) 1 (4.0)
Severe 0 (0) 0 (0) 0 (0)
Left ventricular ejection fraction (%) 65.8±12.6 63.8±14.2 69.3±8.4 0.047
At 1-year follow-up* n=53 n=35 n=18
Effective orifice area (cm2) 1.53±0.41 1.67±0.32 1.27±0.44 <0.001
Indexed effective orifice area (cm2/m2) 1.01±0.28 1.12±0.22 0.81±0.27 <0.001
Maximum aortic valve pressure gradient (mmHg) 20.1±9.5 17.0±8.0 26.2±9.4 <0.001
Mean aortic valve pressure gradient (mmHg) 10.6±5.2 8.5±4.0 14.7±4.8 <0.001
Doppler velocity index 0.55±0.15 0.61±0.12 0.44±0.15 <0.001
Prosthesis-patient mismatch 16 (30.2) 4 (11.4) 12 (66.7) <0.001
Moderate 10 (18.9) 4 (11.4) 6 (33.3)
Severe 6 (11.3) 0 (0.0) 6 (33.3)
Paravalvular leak 25 (47.2) 18 (51.4) 7 (38.9) 0.565
Mild 22 (41.5) 16 (45.7) 6 (33.3)
Moderate 3 (5.7) 2 (5.7) 1 (5.6)
Severe 0 (0) 0 (0) 0 (0)
Left ventricular ejection fraction (%) 66.1±11.8 66.0±13.3 66.4±8.5 0.892
Data are presented as mean±standard deviation or number (%).

















































Baseline Discharge 1 year
p=0.010 p=0.005 p<0.001
Figure 1. Echocardiographic outcomes at baseline, discharge, and 1-year follow-up. 
Effective orifice area (A), indexed effective orifice area (B), and mean aortic valve pressure gradient (C). 
EOA = effective orifice area; iEOA = indexed effective orifice area.
disadvantages, both types of valves have shown comparable clinical outcomes and superior 
hemodynamic outcomes compared with surgical aortic valve replacement; therefore, the use 
of TAVR has recently expanded.1-4) Better hemodynamic benefits are driven from achievement 
of larger EOA in patients who received TAVR than in those who received surgical aortic valve 
replacement. Since the achievement of larger EOA depends on the original size of aortic 
annulus of each patient, the clinical benefit of TAVR toward valve hemodynamics was more 
pronounced in patients with small aortic annulus and selection for adequate TAVR valves 
is crucial to achieve larger EOA in these patients.9)14) There have been studies comparing 
the performance of these two types of valves in small aortic annulus. Mauri et al. reported 
that compared with the balloon-expandable SAPIEN 3 valve, the self-expanding ACURATE 
neo valve showed superior hemodynamic outcomes (iEOA, 0.80 vs. 0.96 cm2/m2, p=0.003; 
mean aortic valve pressure gradient, 14.5 vs. 9.3 mmHg, p<0.001; severe PPM, 22% vs. 3%, 
p=0.004) in German patients with small aortic annulus defined as aortic annular area <400 
mm2 on computed tomography.5) Rogers et al.6) demonstrated similar results in patients 
in the United States with small aortic annulus defined as annular perimeter <73 mm on 
computed tomography. Compared with the balloon-expandable SAPIEN XT or SAPIEN 3 valve, 
the self-expanding CoreValve and Evoult R valves showed better hemodynamic outcomes 
(dimensionless index, 0.53 vs. 0.64, p=0.02; peak aortic valve velocity, 2.4 vs. 1.8 m/sec, 
p<0.001).6) However, it remains uncertain which device performs better in Asian population 
with small aortic annulus. In our study, we specifically focused on Asian patients whose BSA 
was smaller than the Western population, adopted recently proposed definitions for small 
aortic annulus, and also compared the performance of the latest available generations of 
each type of valve with comparable size.9) The improved hemodynamic outcomes were more 
prominent in patients who underwent TAVR with the self-expanding Evolut valve without 
significant differences in paravalvular leak and clinical outcomes, similar to previous studies 
in patients in Europe and the United States.5)6) The main factor to achieve better hemodynamic 
benefits and larger EOA may be driven by supra-annular location in the self-expanding valve 
compared with intra-annular location in the balloon-expandable valve. Recently, Hase et al.15) 
focused on Japanese patients with small aortic annulus defined as mean annulus diameter 
≤23 mm on computed tomography. Compared with the balloon-expandable SAPIEN 3 valve, 
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Figure 2. Incidence of prosthesis-patient mismatch and paravalvular leak at discharge and 1-year follow-up. 
Prosthesis-patient mismatch (A) and paravalvular leak (B). There was no severe paravalvular leak during 1-year follow-up.
the self-expanding Evolut R valve showed superior hemodynamic outcomes (iEOA, 1.08 vs. 
1.2 cm2/m2, p<0.001; mean aortic valve pressure gradient, 12.0 vs. 9.0 mmHg, p<0.001).15) 
However, no significant difference was noted in the incidence of moderate and severe PPM 
which was different from our study. This may be due to the difference in study population with 
smaller BSA compared to the study of ours and Mauri et al.5)
Clinically significant PPM was identified as a predictor of adverse clinical outcomes after 
TAVR.2)9)16) According to the previous studies regarding patients with small aortic annulus who 
received the balloon-expandable SAPIEN valve, the incidence of more than moderate PPM was 
39.4% in the Placement of Aortic Transcatheter Valves (PARTNER) trial and 42.1% in the study 
by Rogers et al.,6) which were slightly higher than the 36.0% in our study.14) On the other hand, 
the incidence of more than moderate PPM after self-expanding Evolut valve implantation in our 
study was considerably lower (8.9%) than a previous study which analyzed the performance of 
self-expanding valves in European patients with small aortic annulus (Evolut R, 24.5%; Evolut 
PRO, 20.5%).17) The greater difference in the incidence of PPM following self-expanding valve 
implantation may be explained by several factors. Our definition of small aortic annulus was 
different from previous studies, as we followed the latest proposals for a mean diameter of 
<23 mm or minimal diameter of ≤21 mm on computed tomography.9) Furthermore, our study 
specifically focused on the Asian population, whose BSA is relatively smaller than Western 
populations.7)8) From the three randomized trials conducted in patients in the United States 
and Canada, Hahn et al.18) reported the expected values of echocardiographic hemodynamic 
assessment after TAVR by valve type and size. The post-procedural EOA after 23 mm SAPIEN 3 
valve implantation in our study was similar to the expected EOA (1.45±0.26 cm2), however, the 
post-procedural EOA after 26 mm Evolut valve implantation was larger than the expected EOA 
(1.69±0.40 cm2). Therefore, since PPM was defined according to iEOA which was calculated 
by dividing EOA by the BSA, the greater difference in the incidence of PPM following self-
expanding Evolut valve implantation may be explained.
This study has several limitations. First, it was a single-center non-randomized study based 
on a limited number of patients with inherent limitations such as differences in the baseline 
clinical, procedural characteristics, and potential confounding factors. For instance, post-
dilation which was more frequently performed the in the self-expanding valve-treated 
patients may have been an additional mechanism for the better hemodynamic outcomes 
apart from supra-annular location of the self-expanding valve. However, the impact of post-
dilation cannot be fully evaluated in the present analysis. Second, we focused on patients 
with small aortic annulus and did not include other aortic annulus sizes, therefore patient 
selection bias may exist. Third, the choice of transcatheter aortic valve type was at the 
discretion of the operating interventional cardiologists. Fourth, 1-year echocardiography was 
not available in all patients.
In conclusion, in Korean patients with small aortic annulus, TAVR with self-expanding valves 
was associated with superior hemodynamic outcomes compared with balloon-expandable 
valves. These findings pave the way for further trials regarding appropriate prosthesis 
selection for TAVR in patients with small aortic annulus.
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Supplementary Table 2
Echocardiographic characteristics at baseline, discharge, and 1-year follow-up between the self-
expanding 23 mm valve-treated patients and balloon-expandable 20 mm valve-treated patient
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